{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:42:35Z","timestamp":1790037755813,"version":"4.0.1"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    This prospective multi\u2010institutional phase II study was designed to assess the efficacy and safety of dose\u2010adjusted\n                    <jats:styled-content style=\"fixed-case\">EPOCH<\/jats:styled-content>\n                    (etoposide, prednisone,\u00a0vincristine, cyclophosphamide and doxorubicin) plus rituximab (\n                    <jats:styled-content style=\"fixed-case\">DA\u2010EPOCH\u2010R<\/jats:styled-content>\n                    ) in untreated patients with poor prognosis large B\u2010cell lymphomas. Eighty\u2010one patients diagnosed with diffuse large B\u2010cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>\n                    ,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a068), primary mediastinal\n                    <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a06) and follicular lymphoma Grade 3b (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a07), with an age\u2010adjusted International Prognostic Index &gt;1, were eligible for analysis. Median age was 60\u00a0years (range: 21\u201377). Sixty\u2010five patients (80\u00b72%) achieved complete response. After a median follow\u2010up time of 64\u00a0months, 10\u2010year event\u2010free survival and overall survival (\n                    <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>\n                    ) were 47\u00b78% and 63\u00b76%, respectively. None of the studied clinical and biological characteristics were associated with poorer outcome. Interestingly, patients with\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      6\n                    <\/jats:italic>\n                    rearrangement achieved a 10\u2010year\n                    <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>\n                    of 100%, while patients with\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      2\n                    <\/jats:italic>\n                    rearrangement exhibited a poorer outcome compared to activated B\u2010cell tumours and germinal centre B\u2010cell without\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      2\n                    <\/jats:italic>\n                    rearranged tumours. Results achieved with\n                    <jats:styled-content style=\"fixed-case\">DA\u2010EPOCH\u2010R<\/jats:styled-content>\n                    showed a good long\u2010term outcome and a tolerable toxicity profile in high\u2010risk large B cell lymphoma patients. Outcome was not affected by tumour cell proliferation or by cell of origin, highlighting the requirement of new biological markers for patient subclassification of high\u2010risk\n                    <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>\n                    patients.\n                  <\/jats:p>","DOI":"10.1111\/bjh.13273","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T01:51:36Z","timestamp":1418953896000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Long\u2010term follow\u2010up of dose\u2010adjusted EPOCH plus rituximab (DA\u2010EPOCH\u2010R) in untreated patients with poor prognosis large B\u2010cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group"],"prefix":"10.1111","volume":"169","author":[{"given":"Noelia","family":"Purroy","sequence":"first","affiliation":[{"name":"Department of Haematology Hospital Universitari Vall d'Hebron Vall d'Hebron Institut de Recerca (VHIR) Universitat Aut\u00f2noma de Barcelona (UAB) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bergua","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital San Pedro Alc\u00e1ntara C\u00e1ceres Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gallur","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Universitari Vall d'Hebron Vall d'Hebron Institut de Recerca (VHIR) Universitat Aut\u00f2noma de Barcelona (UAB) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Prieto","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital San Pedro Alc\u00e1ntara C\u00e1ceres Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Royo Villanova Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Sancho","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Germans Trias i Pujol Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Garc\u00eda\u2010Marco","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Puerta del Hierro Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Castellv\u00ed","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitari Vall d'Hebron Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Montes\u2010Moreno","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitario Marqu\u00e9s de Valdecilla IFIMAV Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Batlle","sequence":"additional","affiliation":[{"name":"Cytogenetics Unit Department of Haematology Hospital Universitario Marqu\u00e9s de Valdecilla IFIMAV Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Gonzalez","family":"de Villambrosia","sequence":"additional","affiliation":[{"name":"Cytogenetics Unit Department of Haematology Hospital Universitario Marqu\u00e9s de Valdecilla IFIMAV Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Carnicero","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital San Pedro Alc\u00e1ntara C\u00e1ceres Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ferrando\u2010Lamana","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital San Pedro Alc\u00e1ntara C\u00e1ceres Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Piris","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitario Marqu\u00e9s de Valdecilla IFIMAV Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Universitari Vall d'Hebron Vall d'Hebron Institut de Recerca (VHIR) Universitat Aut\u00f2noma de Barcelona (UAB) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0113"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox D.","year":"1972","journal-title":"Journal of the Royal Statistical Society"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4490"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2008.057257"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038000"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.5A6646.2005"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06438.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.244"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000324206"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322362"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.7.657"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_19_1","first-page":"1721","article-title":"Two\u2010stage plans for patient accrual in phase II cancer clinical trials","volume":"63","author":"Lee Y.J.","year":"1979","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.945"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.0368"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094151"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3442"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-345256"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.007203"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.10.2810.2810"},{"key":"e_1_2_8_29_1","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3874430"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.4.1178"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/335440a0"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066209"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701344881"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1391"},{"key":"e_1_2_8_37_1","first-page":"686","article-title":"The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI\u201032765), Has Preferential Activity in the ABC Subtype of Relapsed\/Refractory De Novo Diffuse Large B\u2010Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open\u2010Label, Phase 2 Study","volume":"120","author":"Wilson W.H.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4222"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13273","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T19:37:31Z","timestamp":1717616251000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/bjh.13273"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13273","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725283014.793521324","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]},"assertion":[{"value":"2014-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}